A heartbreaking tragedy has reignited a critical debate: should the meningococcal B vaccine be free for all? The sudden death of 16-year-old Levi Syer-Peterson has left his mother, Norliah, and an entire community demanding action. Levi's story is a stark reminder of the devastating impact of this preventable disease, and it's sparking a conversation that's long overdue.
General Practitioners across Victoria are rallying behind Norliah, urging the state government to follow the lead of South Australia, the Northern Territory, and Queensland in funding the meningococcal B vaccine. But here's where it gets controversial: while these states offer the vaccine free of charge, Victorian parents face a hefty bill of $400 to $600 for up to three doses. The Royal Australian College of General Practitioners (RACGP) is throwing its weight behind the cause, advocating for equal access to this life-saving vaccine.
And this is the part most people miss: Meningococcal B is often mistaken for a common bug or virus in its early stages. Norliah shared her son's symptoms—a stiff neck and a tummy ache—which tragically progressed to a fight for his life within hours. One in ten people who contract meningococcal B will die, and this year alone, Australia has seen 72 cases, with 14 in Victoria.
The emotional plea from Norliah is hard to ignore: 'If something's preventable, what are you waiting for?' She's started a petition, determined to ensure no other family endures her pain. But the path to making the vaccine free isn't straightforward. The Meningococcal B vaccine, Bexsero®, is currently only available through the National Immunisation Program (NIP) for Aboriginal and Torres Strait Islander children under 2 and individuals with specific medical conditions. The Pharmaceutical Benefits Advisory Committee (PBAC) must recommend it as a 'designated vaccine' for it to be listed on the NIP, and the pharmaceutical company, GlaxoSmithKline (GSK), hasn't submitted an updated application since 2019.
Here's the catch: Pharmaceutical companies are private entities and can't be forced to apply. The decision to seek NIP listing rests with them, leaving states to consider independent funding. While some states have taken this step, Victoria has yet to follow suit. Is it fair to wait for more deaths before taking action? Should economic considerations outweigh the value of young lives?
The Department of Health, Disability and Ageing is engaging with GSK, hoping for a new submission to PBAC. But the question remains: how many more families will suffer before a solution is found? What do you think? Should the meningococcal B vaccine be free for all, or is the current system sufficient? Share your thoughts in the comments—this is a conversation that needs your voice.
